497 results on '"DiMarchi, Richard D"'
Search Results
2. Superior metabolic improvement of polycystic ovary syndrome traits after GLP1-based multi-agonist therapy
3. Glucose-dependent insulinotropic polypeptide regulates body weight and food intake via GABAergic neurons in mice
4. Transforming obesity: The advancement of multi-receptor drugs
5. GIP receptor agonism improves dyslipidemia and atherosclerosis independently of body weight loss in preclinical mouse model for cardio-metabolic disease
6. GIPR/GLP-1R dual agonist therapies for diabetes and weight loss—chemistry, physiology, and clinical applications
7. GLP-1-mediated delivery of tesaglitazar improves obesity and glucose metabolism in male mice
8. Validation of Mct8/Oatp1c1 dKO mice as a model organism for the Allan-Herndon-Dudley Syndrome
9. Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice
10. Anti-obesity drug discovery: advances and challenges
11. Interaction of a viral insulin-like peptide with the IGF-1 receptor produces a natural antagonist
12. A viral insulin-like peptide is a natural competitive antagonist of the human IGF-1 receptor
13. The glucose-dependent insulinotropic polypeptide (GIP) regulates body weight and food intake via CNS-GIPR signaling
14. Targeted pharmacological therapy restores β-cell function for diabetes remission
15. Phr‐peptide signaling by S. pneumoniae
16. A new quorum-sensing system (TprA/PhrA) for Streptococcus pneumoniae D39 that regulates a lantibiotic biosynthesis gene cluster.
17. Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism
18. Molecular elements in FGF19 and FGF21 defining KLB/FGFR activity and specificity
19. Optimization of peptide-based polyagonists for treatment of diabetes and obesity
20. CNS-targeting pharmacological interventions for the metabolic syndrome
21. Emerging hormonal-based combination pharmacotherapies for the treatment of metabolic diseases
22. GIP receptor agonism improves dyslipidemia and atherosclerosis independently of body weight loss in preclinical mouse model for cardio-metabolic disease
23. Molecular Integration of Incretin and Glucocorticoid Action Reverses Immunometabolic Dysfunction and Obesity
24. Gαs regulates Glucagon-Like Peptide 1 Receptor-mediated cyclic AMP generation at Rab5 endosomal compartment
25. Once Blind, Now We See GLP-1 Molecular Action
26. The Sustained Effects of a Dual GIP/GLP-1 Receptor Agonist, NNC0090-2746, in Patients with Type 2 Diabetes
27. Stereochemical inversion as a route to improved biophysical properties of therapeutic peptides exemplified by glucagon
28. Novel Combinatorial Therapies Involving Leptin: Opportunities for Mechanistic Advances and Therapeutic Translation in Human Diseases
29. Fibroblast activation protein (FAP) as a novel metabolic target
30. Unimolecular Polypharmacy for Treatment of Diabetes and Obesity
31. Reappraisal of GIP Pharmacology for Metabolic Diseases
32. GLP-1/glucagon receptor co-agonism for treatment of obesity
33. Correction: GIP receptor agonism improves dyslipidemia and atherosclerosis independently of body weight loss in preclinical mouse model for cardio-metabolic disease.
34. Author Correction: Targeted pharmacological therapy restores β-cell function for diabetes remission
35. Controlled intramolecular antagonism as a regulator of insulin receptor maximal activity
36. Synthesis of disulfide-rich heterodimeric peptides through an auxiliary N, N-crosslink
37. Synthesis and Biological Assessment of Insulin-Like Analogs with Differential Activity at the Insulin and IGF-1 Receptors
38. Peptide lipidation stabilizes structure to enhance biological function
39. Zn-regulated GTPase metalloprotein activator 1 modulates vertebrate zinc homeostasis
40. A hydrophobic site on the GLP-1 receptor extracellular domain orients the peptide ligand for signal transduction
41. Novel GLP-1R/GIPR co-agonist “twincretin” is neuroprotective in cell and rodent models of mild traumatic brain injury
42. A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents
43. GLP-1–oestrogen attenuates hyperphagia and protects from beta cell failure in diabetes-prone New Zealand obese (NZO) mice
44. Efficacy of glucagon-like peptide-1 and estrogen dual agonist in pancreatic islets protection and pre-clinical models of insulin-deficient diabetes
45. GIP receptor agonism improves dyslipidemia and atherosclerosis independently of body weight in obese mice
46. Peptide Model of the Mutant Proinsulin Syndrome. II. Nascent Structure and Biological Implications
47. Peptide Model of the Mutant Proinsulin Syndrome. I. Design and Clinical Correlation
48. Recent Advances in Incretin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes
49. Optimized clinical performance of growth hormone with an expanded genetic code
50. Optimization of the C-terminal Sequence in Glucagon to Maximize Receptor Affinity
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.